BofA lowered the firm’s price target on Apellis (APLS) to $41 from $44 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Needham healthcare analysts hold analyst/industry conference call
- Apellis price target raised to $31 from $30 at Scotiabank
- Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
- Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
- Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects